• Product name
    Anti-IGF1 Receptor antibody
    See all IGF1 Receptor primary antibodies
  • Description
    Rabbit polyclonal to IGF1 Receptor
  • Host species
  • Specificity
    This antibody detects endogenous levels of total IGF1 Receptor protein. Crossreacts with insulin receptor (P06213) and insulin receptor related protein (P14616).
  • Tested applications
    Suitable for: IHC-P, WB, IHC-Frmore details
  • Species reactivity
    Reacts with: Mouse, Rat, Human
  • Immunogen

    The antiserum was produced against synthesized non phosphopeptide derived from human IGF1 Receptor around the phosphorylation site of tyrosine1161.

  • Positive control
    • WB: HEK-293 and SK-OV3 cells treated with 10 mU/ml insulin. IHC: Human breast carcinoma and brain tumor tissues.



Our Abpromise guarantee covers the use of ab39675 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

Application Abreviews Notes
IHC-P 1/50 - 1/100. Perform heat mediated antigen retrieval with citrate buffer pH 6 before commencing with IHC staining protocol.
WB 1/500 - 1/1000. Predicted molecular weight: 155 kDa.
IHC-Fr Use at an assay dependent concentration. PubMed: 21873981


  • Function
    Receptor tyrosine kinase which mediates actions of insulin-like growth factor 1 (IGF1). Binds IGF1 with high affinity and IGF2 and insulin (INS) with a lower affinity. The activated IGF1R is involved in cell growth and survival control. IGF1R is crucial for tumor transformation and survival of malignant cell. Ligand binding activates the receptor kinase, leading to receptor autophosphorylation, and tyrosines phosphorylation of multiple substrates, that function as signaling adapter proteins including, the insulin-receptor substrates (IRS1/2), Shc and 14-3-3 proteins. Phosphorylation of IRSs proteins lead to the activation of two main signaling pathways: the PI3K-AKT/PKB pathway and the Ras-MAPK pathway. The result of activating the MAPK pathway is increased cellular proliferation, whereas activating the PI3K pathway inhibits apoptosis and stimulates protein synthesis. Phosphorylated IRS1 can activate the 85 kDa regulatory subunit of PI3K (PIK3R1), leading to activation of several downstream substrates, including protein AKT/PKB. AKT phosphorylation, in turn, enhances protein synthesis through mTOR activation and triggers the antiapoptotic effects of IGFIR through phosphorylation and inactivation of BAD. In parallel to PI3K-driven signaling, recruitment of Grb2/SOS by phosphorylated IRS1 or Shc leads to recruitment of Ras and activation of the ras-MAPK pathway. In addition to these two main signaling pathways IGF1R signals also through the Janus kinase/signal transducer and activator of transcription pathway (JAK/STAT). Phosphorylation of JAK proteins can lead to phosphorylation/activation of signal transducers and activators of transcription (STAT) proteins. In particular activation of STAT3, may be essential for the transforming activity of IGF1R. The JAK/STAT pathway activates gene transcription and may be responsible for the transforming activity. JNK kinases can also be activated by the IGF1R. IGF1 exerts inhibiting activities on JNK activation via phosphorylation and inhibition of MAP3K5/ASK1, which is able to directly associate with the IGF1R.
    When present in a hybrid receptor with INSR, binds IGF1. PubMed:12138094 shows that hybrid receptors composed of IGF1R and INSR isoform Long are activated with a high affinity by IGF1, with low affinity by IGF2 and not significantly activated by insulin, and that hybrid receptors composed of IGF1R and INSR isoform Short are activated by IGF1, IGF2 and insulin. In contrast, PubMed:16831875 shows that hybrid receptors composed of IGF1R and INSR isoform Long and hybrid receptors composed of IGF1R and INSR isoform Short have similar binding characteristics, both bind IGF1 and have a low affinity for insulin.
  • Tissue specificity
    Found as a hybrid receptor with INSR in muscle, heart, kidney, adipose tissue, skeletal muscle, hepatoma, fibroblasts, spleen and placenta (at protein level). Expressed in a variety of tissues. Overexpressed in tumors, including melanomas, cancers of the colon, pancreas prostate and kidney.
  • Involvement in disease
    Insulin-like growth factor 1 resistance
  • Sequence similarities
    Belongs to the protein kinase superfamily. Tyr protein kinase family. Insulin receptor subfamily.
    Contains 4 fibronectin type-III domains.
    Contains 1 protein kinase domain.
  • Post-translational
    Autophosphorylated on tyrosine residues in response to ligand binding. Autophosphorylation occurs in trans, i.e. one subunit of the dimeric receptor phosphorylates tyrosine residues on the other subunit. Autophosphorylation occurs in a sequential manner; Tyr-1165 is predominantly phosphorylated first, followed by phosphorylation of Tyr-1161 and Tyr-1166. While every single phosphorylation increases kinase activity, all three tyrosine residues in the kinase activation loop (Tyr-1165, Tyr-1161 and Tyr-1166) have to be phosphorylated for optimal activity. Can be autophosphorylated at additional tyrosine residues (in vitro). Autophosphorylated is followed by phosphorylation of juxtamembrane tyrosines and C-terminal serines. Phosphorylation of Tyr-980 is required for IRS1- and SHC1-binding. Phosphorylation of Ser-1278 by GSK-3beta restrains kinase activity and promotes cell surface expression, it requires a priming phosphorylation at Ser-1282. Dephosphorylated by PTPN1.
    Polyubiquitinated at Lys-1168 and Lys-1171 through both 'Lys-48' and 'Lys-29' linkages, promoting receptor endocytosis and subsequent degradation by the proteasome. Ubiquitination is facilitated by pre-existing phosphorylation.
    Sumoylated with SUMO1.
    Controlled by regulated intramembrane proteolysis (RIP). Undergoes metalloprotease-dependent constitutive ectodomain shedding to produce a membrane-anchored 52 kDa C-Terminal fragment which is further processed by presenilin gamma-secretase to yield an intracellular 50 kDa fragment.
  • Cellular localization
    Cell membrane.
  • Information by UniProt
  • Database links
  • Alternative names
    • CD221 antibody
    • CD221 antigen antibody
    • IGF 1 receptor antibody
    • IGF 1R antibody
    • IGF I receptor antibody
    • IGF-I receptor antibody
    • Igf1r antibody
    • IGF1R_HUMAN antibody
    • IGFIR antibody
    • IGFIRC antibody
    • IGFR antibody
    • Insulin like growth factor 1 receptor antibody
    • Insulin like growth factor 1 receptor precursor antibody
    • Insulin-like growth factor 1 receptor beta chain antibody
    • Insulin-like growth factor I receptor antibody
    • JTK13 antibody
    • MGC142170 antibody
    • MGC142172 antibody
    • MGC18216 antibody
    • Soluble IGF1R variant 1 antibody
    • Soluble IGF1R variant 2 antibody
    see all


  • Paraffin-embedded human brain tumor (Ependymoma) tissue stained for IGF1 Receptor using ab39675 at 1/50 dilution in immunohistochemical analysis.

  • Western blot analysis using IGF1 Receptor antibody (ab39675, Lane 1, 2 and 3) and IGF1 Receptor (phospho-Tyr1161) antibody (ab39398, Lane 4 and 5). Lane 1 and 5 treated with insulin (10mU/ml).
  • Paraffin-embedded human breast carcinoma tissue stained for IGF1 Receptor using ab39675 at 1/50 dilution in immunohistochemical analysis.

    Ab39675 staining human IGF1 Receptor in human breast carcinoma by immunohistochemistry using paraffin embedded tissue.


This product has been referenced in:
  • Huang FT  et al. The novel long intergenic noncoding RNA UCC promotes colorectal cancer progression by sponging miR-143. Cell Death Dis 8:e2778 (2017). WB ; Human . Read more (PubMed: 28492554) »
  • Lin S  et al. CD215+ Myeloid Cells Respond to Interleukin 15 Stimulation and Promote Tumor Progression. Front Immunol 8:1713 (2017). Read more (PubMed: 29255466) »

See all 19 Publications for this product

Customer reviews and Q&As

Immunocytochemistry/ Immunofluorescence
Human Cell (HEK293)
Yes - 0.1% Triton X100
Blocking step
Serum as blocking agent for 2 hour(s) and 0 minute(s) · Concentration: 5% · Temperature: 25°C

Abcam user community

Verified customer

Submitted Jul 18 2017

Western blot
Loading amount
40 µg
Gel Running Conditions
Reduced Denaturing (10% SDS PAGE)
Mouse Tissue lysate - whole (LIVER)
Blocking step
Milk as blocking agent for 2 hour(s) and 0 minute(s) · Concentration: 5% · Temperature: 25°C

Abcam user community

Verified customer

Submitted Jun 09 2014

Abcam guarantees this product to work in the species/application used in this Abreview.
Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections)
Human Tissue sections (Brain tumor (Ependymoma))
Brain tumor (Ependymoma)
Antigen retrieval step
Heat mediated - Buffer/Enzyme Used: Citrate pH=6
Blocking step
BSA as blocking agent for 45 minute(s) · Concentration: 0.5% · Temperature: 25°C

Abcam user community

Verified customer

Submitted Aug 10 2011


Sign up